Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in treatment-resistant major depressive disorder
NCT04101474Completed
- Sponsor
- Assiut University
- Start
- Sep 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of ketamine in major depressive disorder (MDD), sponsored by Assiut University. Primary endpoints: Role of Ketamine as Antidepressant at 1 year and Effect of Ketamine on Suicidality at 1 year. Started Sep 2020; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04101474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101474.